NASDAQ:OMER - Omeros Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.72 -0.12 (-0.60 %)
(As of 05/27/2018 03:59 AM ET)
Previous Close$19.72
Today's Range$19.52 - $20.10
52-Week Range$8.36 - $27.09
Volume552,592 shs
Average Volume1.39 million shs
Market Capitalization$958.13 million
P/E Ratio-24.96
Dividend YieldN/A
Beta3.6

About Omeros (NASDAQ:OMER)

Omeros logoOmeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000

Debt

Debt-to-Equity Ratio-2.91
Current Ratio3.19
Quick Ratio3.18

Price-To-Earnings

Trailing P/E Ratio-24.96
Forward P/E Ratio-8.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.83 million
Price / Sales14.69
Cash FlowN/A
Price / CashN/A
Book Value($0.60) per share
Price / Book-32.87

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-53,480,000.00
Net Margins-126.38%
Return on EquityN/A
Return on Assets-52.29%

Miscellaneous

Employees173
Outstanding Shares48,290,000

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros (NASDAQ:OMER) posted its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.05. The biopharmaceutical company earned $1.59 million during the quarter, compared to the consensus estimate of $2.08 million. The company's revenue for the quarter was down 87.0% compared to the same quarter last year. During the same period last year, the company earned ($0.34) earnings per share. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

7 Wall Street analysts have issued 12 month price targets for Omeros' stock. Their forecasts range from $4.00 to $75.00. On average, they anticipate Omeros' share price to reach $26.5729 in the next year. View Analyst Ratings for Omeros.

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:
  • 1. HC Wainwright analysts commented, "We remind investors that, only last year, Omeros announced that it had settled litigation directed to an ANDA filing by Par Sterile Products, LLC and Par Pharmaceutical, Inc. As in the settlement with Par, this agreement with Lupin includes Lupin’s acknowledgment and confirmation of the validity of all asserted patents for OMIDRIA as well as overall terms and market entry date similar to those set forth in the Par agreement—we note that Par has agreed not to launch a generic version of OMIDRIA until the earliest. The expiration date of the last-to-expire of Omeros’ asserted patents for OMIDRIA is October 23, 2033. The litigation against Lupin began in 2017 after Omeros received a Paragraph IV certification from Lupin in connection with Lupin’s filing of an ANDA seeking the FDA’s approval to market a generic version of OMIDRIA." (5/25/2018)
  • 2. Maxim Group analysts commented, "Prior to hitting the pass thru speed bump in January (and it’s just a speed bump), Omidria revenue grew to $22M in 3Q17. We expect these numbers to return in 4Q and for Omidria to grow with several factors to watch between now and then – 1Q expectations, getting back to pass-thru in October, impact of the VA and the healthy balance sheet." (5/7/2018)
  • 3. WBB Securities analysts commented, "We are therefore continuing our Strong Buy recommendation with a continued One-Year Target Price of $75. Pass-through enables physicians to prescribe and bill Medicare for the cost of designated drugs in addition to the fixed fee for which treatment is administered. The text of the bill states, “In the case of a drug or biological whose period of pass-through status under this paragraph ended on December 31, 2017, and for which payment under this subsection was packaged into a payment for a covered OPD service (or group of services) furnished beginning January 1, 2018, such pass- through status shall be extended for a 2-year period beginning on October 1, 2018.” While not a guarantee, we also believe that this is a logical next step to permanent reimbursement by CMS, which takes place with the vast majority of all drugs. OMIDRIA is a combination drug that is administered during intra-ocular surgery." (3/26/2018)
  • 4. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (3/1/2018)

Who are some of Omeros' key competitors?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 60)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 58)
  • Dr. Pamela Pierce Palmer M.D., Ph.D., Co-Founder (Age 55)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 61)

Has Omeros been receiving favorable news coverage?

News headlines about OMER stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros earned a media sentiment score of 0.24 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Omeros' major shareholders?

Omeros' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.21%), UBS Group AG (0.82%), Stifel Financial Corp (0.72%), Schwab Charles Investment Management Inc. (0.46%), Baird Financial Group Inc. (0.22%) and United Capital Financial Advisers LLC (0.22%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Which major investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., New York State Common Retirement Fund, Teacher Retirement System of Texas, California State Teachers Retirement System and Allianz Asset Management GmbH. View Insider Buying and Selling for Omeros.

Which major investors are buying Omeros stock?

OMER stock was purchased by a variety of institutional investors in the last quarter, including Baird Financial Group Inc., BlackRock Inc., UBS Group AG, DekaBank Deutsche Girozentrale, Cypress Capital Group, Claraphi Advisory Network LLC, Russell Investments Group Ltd. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $19.72.

How big of a company is Omeros?

Omeros has a market capitalization of $958.13 million and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Omeros employs 173 workers across the globe.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros (OMER)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  691
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Omeros (NASDAQ:OMER) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Omeros in the last 12 months. Their average twelve-month price target is $26.5729, suggesting that the stock has a possible upside of 34.75%. The high price target for OMER is $75.00 and the low price target for OMER is $4.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.432.432.882.67
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $26.5729$26.43$31.5714$36.1667
Price Target Upside: 34.75% upside117.53% upside186.75% upside98.72% upside

Omeros (NASDAQ:OMER) Consensus Price Target History

Price Target History for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2018HC WainwrightSet Price TargetBuy$34.00LowView Rating Details
5/16/2018WedbushReiterated RatingNeutral ➝ Hold$19.00 ➝ $20.00LowView Rating Details
5/13/2018Maxim GroupSet Price TargetBuy$25.00HighView Rating Details
3/26/2018WBB SecuritiesReiterated RatingBuy$75.00HighView Rating Details
3/2/2018Needham & Company LLCDowngradeBuy ➝ Hold$9.01HighView Rating Details
3/1/2018Cantor FitzgeraldSet Price TargetHold$19.00HighView Rating Details
2/14/2018Bank of AmericaBoost Price Target$2.44 ➝ $4.00LowView Rating Details
11/2/2017CowenDowngradeOutperform ➝ Market PerformN/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
12/5/2016UBSReiterated RatingReduceN/AView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 ➝ $8.63N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Omeros (NASDAQ:OMER) Earnings History and Estimates Chart

Earnings by Quarter for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER) Earnings Estimates

2018 EPS Consensus Estimate: ($2.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.64)($0.64)($0.64)
Q3 20181($0.65)($0.65)($0.65)
Q4 20181($0.64)($0.64)($0.64)

Omeros (NASDAQ OMER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/10/2018Q1 2018($0.57)($0.62)$2.08 million$1.59 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.22)($0.25)$21.94 million$13.76 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.34)($0.16)$17.82 million$21.66 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.23)$14.63 million$17.15 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.48)($0.20)$12.71 million$12.91 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.35)($0.37)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.38)($0.46)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.38)($0.24)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.42)($0.30)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.52)($0.33)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.40)($0.35)ViewN/AView Earnings Details
8/10/2010Q2 2010($0.34)($0.37)ViewN/AView Earnings Details
5/12/2010Q1 2010($0.33)($0.31)ViewN/AView Earnings Details
3/31/2010Q4 2009($0.27)($0.28)ViewN/AView Earnings Details
11/19/2009Q3 2009($0.33)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Omeros (NASDAQ:OMER) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Omeros (NASDAQ OMER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 46.37%
Insider Trading History for Omeros (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Omeros (NASDAQ OMER) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Michael A JacobsenVPSell23,792$23.80$566,249.6019,480View SEC Filing  
1/3/2018Michael A JacobsenVPSell1,020$22.45$22,899.008,520View SEC Filing  
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.0019,500View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.002,650View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.0040,067View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.841,987,025View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.001,987,025View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.401,987,025View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.601,801,381View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00179,597View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00179,497View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00179,497View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00179,497View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00179,497View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00179,497View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.0049,467View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00138,426View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16185,182View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Omeros (NASDAQ OMER) News Headlines

Source:
DateHeadline
Omeros (OMER) Rating Reiterated by HC WainwrightOmeros (OMER) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 25 at 2:33 PM
Omeros (OMER) Expected to Announce Quarterly Sales of $2.59 MillionOmeros (OMER) Expected to Announce Quarterly Sales of $2.59 Million
www.americanbankingnews.com - May 25 at 5:59 AM
BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin ...BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin ...
www.reuters.com - May 24 at 9:12 AM
Form 8-K OMEROS CORP For: May 22Form 8-K OMEROS CORP For: May 22
www.streetinsider.com - May 24 at 9:12 AM
Omeros (OMER) Announces Settlement of Infringement Suit Against ANDA Filer LupinOmeros (OMER) Announces Settlement of Infringement Suit Against ANDA Filer Lupin
www.streetinsider.com - May 24 at 9:12 AM
Omeros Announces Settlement of Infringement Suit Against ANDA Filer LupinOmeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
finance.yahoo.com - May 24 at 9:12 AM
Zacks: Brokerages Expect Omeros (OMER) to Post -$0.62 EPSZacks: Brokerages Expect Omeros (OMER) to Post -$0.62 EPS
www.americanbankingnews.com - May 23 at 1:14 AM
Wedbush Weighs in on Omeros Q2 2018 Earnings (OMER)Wedbush Weighs in on Omeros' Q2 2018 Earnings (OMER)
www.americanbankingnews.com - May 21 at 1:04 AM
Omeros Corporation: What Do The Q1 2018 Earnings Foretell?Omeros Corporation: What Do The Q1 2018 Earnings Foretell?
seekingalpha.com - May 18 at 10:18 AM
Omeros (OMER) Receives Hold Rating from WedbushOmeros (OMER) Receives Hold Rating from Wedbush
www.americanbankingnews.com - May 16 at 9:24 PM
Omeros (OMER) VP Michael A. Jacobsen Sells 23,792 SharesOmeros (OMER) VP Michael A. Jacobsen Sells 23,792 Shares
www.americanbankingnews.com - May 16 at 7:34 PM
Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease InnovatorsRounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators
seekingalpha.com - May 16 at 9:41 AM
Maxim Group Analysts Give Omeros (OMER) a $25.00 Price TargetMaxim Group Analysts Give Omeros (OMER) a $25.00 Price Target
www.americanbankingnews.com - May 14 at 12:42 PM
Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, Presidents Healthcare PlansYour Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President's Healthcare Plans
seekingalpha.com - May 14 at 10:29 AM
Todays Research Reports on Trending Tickers: Omeros and bluebird bioToday's Research Reports on Trending Tickers: Omeros and bluebird bio
finance.yahoo.com - May 14 at 10:29 AM
Omeros (OMER) Upgraded at ValuEngineOmeros (OMER) Upgraded at ValuEngine
www.americanbankingnews.com - May 12 at 12:39 PM
Omeros (OMER) Given a $34.00 Price Target at HC WainwrightOmeros (OMER) Given a $34.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 11 at 8:05 PM
Here's Why Omeros Corporation Stock Is Surging TodayHere's Why Omeros Corporation Stock Is Surging Today
finance.yahoo.com - May 11 at 5:03 PM
Heres Why Omeros Corporation Stock Is Surging TodayHere's Why Omeros Corporation Stock Is Surging Today
www.fool.com - May 11 at 3:16 PM
Omeros up 23% on preparations for BLA for OMS721Omeros up 23% on preparations for BLA for OMS721
seekingalpha.com - May 11 at 1:51 PM
Omeros (OMER) CEO Gregory Demopulos on Q1 2018 Results - Earnings Call TranscriptOmeros' (OMER) CEO Gregory Demopulos on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:00 AM
Omeros: 1Q Earnings SnapshotOmeros: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 10:00 AM
Todays Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros CorporationToday's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation
finance.yahoo.com - May 11 at 10:00 AM
Edited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:00 AM
Omeros (OMER) Announces Quarterly  Earnings Results, Misses Estimates By $0.27 EPSOmeros (OMER) Announces Quarterly Earnings Results, Misses Estimates By $0.27 EPS
www.americanbankingnews.com - May 10 at 8:29 PM
Omeros (OMER) Misses Q1 EPS by 19cOmeros (OMER) Misses Q1 EPS by 19c
www.streetinsider.com - May 10 at 4:52 PM
Omeros Corporation Reports First Quarter 2018 Financial ResultsOmeros Corporation Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 4:52 PM
Omeros (OMER) Raised to "Hold" at BidaskClubOmeros (OMER) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - May 10 at 12:36 AM
Lucky Seven: Omeros Moves, Array BioPharma May Be NextLucky Seven: Omeros Moves, Array BioPharma May Be Next
seekingalpha.com - May 8 at 4:52 PM
Stock Performance Review on Biotech Industry -- Neptune Technologies & Bioressources, NewLink Genetics, OHR ...Stock Performance Review on Biotech Industry -- Neptune Technologies & Bioressources, NewLink Genetics, OHR ...
www.prnewswire.com - May 8 at 9:05 AM
Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018
finance.yahoo.com - May 7 at 4:55 PM
Omeros (OMER) Earns Buy Rating from Maxim GroupOmeros (OMER) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - May 7 at 2:58 PM
Omeros (OMER) Expected to Announce Quarterly Sales of $2.24 MillionOmeros (OMER) Expected to Announce Quarterly Sales of $2.24 Million
www.americanbankingnews.com - May 7 at 2:52 AM
Omeros (OMER) Given Average Rating of "Hold" by BrokeragesOmeros (OMER) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 6 at 3:55 PM
 Brokerages Expect Omeros (OMER) to Announce -$0.53 Earnings Per Share Brokerages Expect Omeros (OMER) to Announce -$0.53 Earnings Per Share
www.americanbankingnews.com - May 5 at 3:11 PM
Omeros (OMER) Raised to "Hold" at ValuEngineOmeros (OMER) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 3 at 11:10 PM
Omeros (OMER) Given a $34.00 Price Target by HC Wainwright AnalystsOmeros (OMER) Given a $34.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 3 at 12:52 PM
Reader Inquiry: Whats The Outlook For Omeros After The Recent Rebound?Reader Inquiry: What's The Outlook For Omeros After The Recent Rebound?
seekingalpha.com - May 1 at 8:56 AM
Omeros (OMER) Set to Announce Quarterly Earnings on TuesdayOmeros (OMER) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 6:32 AM
Omeros Corporation: Substantial Value Added To The HSCT-TMA FranchiseOmeros Corporation: Substantial Value Added To The HSCT-TMA Franchise
seekingalpha.com - April 30 at 10:07 AM
BRIEF-FDA Grants Breakthrough Therapy Designation To Omeros Masp-2 Inhibitor Oms721BRIEF-FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721
www.reuters.com - April 26 at 4:48 PM
Omeros (OMER) Says it Was Granted FDA Breakthrough Therapy Designation for MASP-2 Inhibitor OMS721Omeros (OMER) Says it Was Granted FDA Breakthrough Therapy Designation for MASP-2 Inhibitor OMS721
www.streetinsider.com - April 26 at 4:48 PM
FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic MicroangiopathyFDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
finance.yahoo.com - April 26 at 4:48 PM
Omeros (OMER) Expected to Post Quarterly Sales of $2.24 MillionOmeros (OMER) Expected to Post Quarterly Sales of $2.24 Million
www.americanbankingnews.com - April 20 at 2:34 AM
-$0.53 Earnings Per Share Expected for Omeros (OMER) This Quarter-$0.53 Earnings Per Share Expected for Omeros (OMER) This Quarter
www.americanbankingnews.com - April 18 at 3:08 PM
Omeros (OMER) Raised to "Hold" at Zacks Investment ResearchOmeros (OMER) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:43 PM
Omeros Corporation: Elucidating Formulary Expansion At The VAOmeros Corporation: Elucidating Formulary Expansion At The VA
seekingalpha.com - April 13 at 9:16 AM
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIAOmeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA
www.businesswire.com - April 13 at 9:16 AM
Omeros (OMER) Announces Upcoming Presentations of New Data on OMIDRIA at ASCRSOmeros (OMER) Announces Upcoming Presentations of New Data on OMIDRIA at ASCRS
www.streetinsider.com - April 13 at 9:16 AM
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery MeetingOmeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
finance.yahoo.com - April 13 at 9:16 AM

SEC Filings

Omeros (NASDAQ:OMER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Omeros (NASDAQ:OMER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Omeros (NASDAQ OMER) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.